Related by context. All words. (Click for frequent words.) 87 p = #.# [004] 83 p = 79 P = .# 74 % CI #.#-#.# [002] 72 placebo p = 71 n = 71 % CI #.#-#.# [006] 71 confidence interval CI 70 placebo p 68 p = .# [002] 68 median PFS 67 ≥ 67 CI -#.# 67 % CI #.#-#.# [003] 67 placebo 67 univariate analysis 66 secondary endpoint 65 CI = 65 ± 65 lopinavir r arm 64 % CI #.#-#.# [007] 64 p = NS 64 CI #.#-#.# [002] 64 statistically significant p 64 postoperatively 64 posttreatment 64 Secondary endpoints included 64 LVEF 63 DAS# [002] 63 r = 63 % CI #.#-#.# [008] 63 MADRS score 63 -#.# ± [002] 63 sd = 62 interquartile range 62 confidence interval #.#-#.# 62 ± SD 62 mg QD 62 % Confidence Interval 62 creatinine ratio 62 preoperative 62 nonsignificant 61 -#.# mg dL [002] 61 CI #.#-#.# [001] 61 biochemical recurrence 61 preoperatively 61 % CI #.#-#.# [001] 61 HbA 1c levels 61 statistically significant p = 61 nonfatal MI 61 progression TTP 61 P ≤ 60 lumbar spine BMD 60 highest tertile 60 statistically significant improvement 60 LV ejection fraction 60 IPSS 60 primary endpoint 60 hip BMD 60 Secondary endpoints include 60 WOMAC pain 60 leukopenia 60 pg ml 60 Rating Scale MADRS 60 IU mL 60 oxycodone CR 60 mg d 60 Psoriasis Area 60 Median PFS 60 mm Hg 60 lowest tertile 60 binary restenosis 59 p = .# [001] 59 MACCE 59 postintervention 59 mcg QD 59 postoperative 59 HAQ DI 59 postop 59 achieved ACR# 59 ng mL 59 p = #.# [003] 59 virologic response 59 μmol L 59 = #.#-#.# 59 comparator arm 59 Secondary endpoints 59 statistically significant 59 laboratory abnormalities 59 statistically significant reduction 59 Kaplan Meier analysis 59 PANSS scores 59 mg dL 59 Hazard Ratio HR 59 g dL 59 ‰ ¥ 59 QTcF 59 copies mL 59 5-FU/LV 59 Montgomery Åsberg Depression 59 pg mL 59 lispro 59 reach statistical significance 59 mg Lucentis 59 mcg BID 58 GERD symptom 58 plus methotrexate 58 -#.# mg dL [001] 58 HBeAg negative patients 58 HbA1c levels 58 confidence intervals CIs 58 CR nPR 58 ng dL 58 diameter stenosis 58 mg kg dose 58 biochemical relapse 58 achieved statistical significance 58 dyspnea 58 left ventricular systolic 58 HbA 1c 58 placebo fluoxetine 58 #mg/day [001] 58 demonstrated statistically significant 58 nonobese 58 reinfarction 58 ipsilateral stroke 58 definite stent thrombosis 58 HDRS 58 x ULN 58 mg kg 58 ADAS cog 58 methotrexate monotherapy 58 HIV RNA 58 primary efficacy endpoint 58 normotensive 58 timepoint 58 subscales 57 univariate 57 UPDRS 57 mg BID 57 adjunctive placebo 57 PANSS 57 EDSS score 57 intima media thickness 57 mL/min/#.# m 2 57 mRS 57 pCR 57 systolic function 57 femoral neck BMD 57 ropivacaine 57 periprocedural 57 BMI z 57 EBRT 57 tertile 57 MMSE score 57 p ≤ 57 severe hypoglycemic 57 â ‰ ¥ 57 creatinine clearance 57 Postoperative 57 XIENCE V PROMUS Stent 57 log# 57 Expanded Disability Status 57 timepoints 57 SGRQ 57 refractory ischemia 57 biopsy Gleason 57 ipsilateral 57 REYATAZ r arm 57 Lucentis monotherapy 57 preintervention 57 FOLFIRI alone 57 PaO 2 57 systolic BP 57 #mg QD [001] 57 atazanavir ritonavir 57 pT3 57 PANSS total 57 secondary endpoints 57 left ventricular LV 57 virologic failure 57 nondiabetic patients 57 Median progression 57 MADRS 57 HBeAg seroconversion 57 HCV RNA 57 symptom severity 57 evaluable 57 HOMA IR 57 baseline HbA1c 57 chlorambucil 57 mg TID 57 4mg/kg 57 target vessel revascularization 57 subscale scores 57 Visual Analogue Scale VAS 57 pmol L 57 #.#/#.# mmHg [001] 56 #mg BID [001] 56 mg ustekinumab 56 lopinavir r 56 composite endpoint 56 serum concentrations 56 mcg kg 56 alanine aminotransferase 56 recurrent VTE 56 WOMAC scores 56 plus MTX 56 Viread Emtriva Sustiva 56 Disease Activity 56 MMSE scores 56 mitoxantrone 56 HbA1C levels 56 febrile neutropenia 56 PSA nadir 56 LAB GHRH 56 6MWD 56 multivariate adjustment 56 tirofiban 56 nonsignificant difference 56 multivariate analysis 56 distant metastasis 56 μg mL 56 tertiles 56 myocardial infarction MI 56 log# copies mL 56 covariate 56 mg dose 56 Montgomery Asberg Depression 56 mmHg 56 preoperative PSA 56 nonresponders 56 clinically meaningful improvement 56 peripheral edema 56 ng ml 56 pegylated interferon alfa 2b 56 clodronate 56 -#.# p = 56 mL kg 56 dapagliflozin plus 56 Index CDAI 56 stent binary restenosis 56 posttransplant 56 nonfatal myocardial infarction 56 ejection fractions 56 mmHg diastolic 56 leukocyte count 56 femoral neck 56 Hazard Ratio = 56 mTSS 56 free survival PFS 56 IRLS 56 Target Lesion Revascularization TLR 56 endometrial thickness 56 cerebrovascular events 56 seminal vesicle invasion 56 NIHSS 56 receiving ISENTRESS 55 RLAI 55 multivariable analysis 55 ABC/3TC 55 contralateral 55 liver histology 55 HRQoL 55 LPV r 55 CDAI 55 mmol l 55 DAS# scores 55 Pred Forte 55 estimated glomerular filtration 55 leucopenia 55 pooled comparator 55 events AEs 55 nasopharyngitis 55 Postoperatively 55 tiotropium 55 FEV1 55 desvenlafaxine succinate 55 NIH CPSI 55 neutrophil count 55 colorectal adenoma 55 ug dose 55 incontinence episodes 55 EDSS scores 55 discontinuations due 55 atheroma volume 55 tipranavir r 55 NNT = 55 copies ml 55 systemic embolism 55 peginterferon alfa 2a 55 lymphopenia 55 neutrophil counts 55 Score DAS# 55 PASI scores 55 mmol L 55 tolterodine ER 55 FOLPI 55 advanced adenomas 55 MetS 55 ADAS Cog 55 plus dexamethasone 55 #mg QD [002] 55 systolic dysfunction 55 nmol L 55 Negative Syndrome 55 infarct size 55 prespecified 55 erythrocyte sedimentation rate 55 reintervention 55 prospectively defined 55 IBDQ 55 comorbidities 55 CrCl 55 DAS# remission 55 CCyR 55 rheumatoid factor 55 PCa 55 fasting insulin 55 renal insufficiency 55 nmol liter 55 Crohn Disease Activity 55 plus medroxyprogesterone acetate 55 radiotherapy RT 55 Primary endpoints 55 serum HCV RNA 55 lumbar spine bone 55 Kaplan Meier 55 -#.# log# 55 extrapyramidal symptoms 55 eGFR 55 carotid IMT 55 Zometa hazard 55 Unified Parkinson Disease 55 International Prostate Symptom 55 β = 55 Secondary efficacy endpoints 55 PSADT 55 Visual Analog Scale 55 WOMAC 55 retinal thickness 55 plasma glucose 55 RGT arm 55 advanced adenoma 55 TAXUS p value 55 histologic 55 μg kg 55 recurrent ischemia 55 serum IGF 55 ng dl 55 inflammatory lesions 55 glycated hemoglobin HbA1c 55 covariates 54 PREZISTA ritonavir 54 tamsulosin 54 TAXUS Express Stent 54 ACR# [002] 54 Preoperatively 54 NYHA class 54 Flu Cy 54 univariate analyzes 54 hours postdose 54 macroalbuminuria 54 #mg BID [003] 54 saline placebo 54 hsCRP levels 54 serologically active patients 54 Brief Psychiatric 54 CC genotype 54 severe exacerbations 54 SCr 54 alanine aminotransferase ALT 54 paresthesias 54 elevated transaminases 54 certolizumab 54 locoregional disease 54 df = 54 FOLFOX4 54 poststroke 54 doxorubicin docetaxel 54 ß = 54 serum phosphorus 54 lymphovascular invasion 54 albumin excretion rate 54 mcg albinterferon alfa 2b 54 lymph node metastasis 54 Hazard Ratio 54 Baseline characteristics 54 achieved PASI 54 experienced virologic failure 54 annualized relapse 54 vertebral fracture 54 postoperative complication 54 TT genotype 54 #.#/#.# mm Hg [003] 54 proximal DVT 54 T2 lesion volume 54 infarcts 54 TURBT 54 morphometric vertebral fractures 54 severe neutropenia 54 DAS# CRP 54 Thal Dex 54 nadroparin 54 IIIa inhibitors 54 QoL 54 sham injections 54 HF hospitalization 54 tibiofemoral 54 receiving VICTRELIS 54 AUC0 54 multivariate Cox 54 coronary stenosis 54 diastolic BP 54 HbA1c 54 mIU L 54 log# IU mL 54 FOLFOX 54 hypoglycemic events 54 CSBM 54 mmHg systolic 54 umol L 54 euthyroid 54 TEAEs 54 placebo dexamethasone 54 #.#/#.# mm Hg [001] 54 g dl 54 ETDRS 54 diastolic hypertension 54 octreotide LAR 54 mean baseline A1C 54 CDAI score 54 #mg/kg [002] 54 tumor progression TTP 54 QRS duration 54 recurrent venous thromboembolism 54 Free Survival PFS 54 infliximab monotherapy 54 NYHA functional class 54 peginterferon alfa 2b 54 methacholine challenge 54 -#.# ± [001] 54 hematologic toxicity 54 multivariate analyzes 54 PCWP 54 undetectable HBV DNA 54 hypophosphatemia 54 EQ 5D 54 proteinuria 53 Kaplan Meier estimates 53 statistically significant differences 53 PSQI 53 incidence ≥ 53 ATV RTV 53 serum testosterone 53 femoral neck fracture 53 Cmax 53 ≤ 53 AOR = 53 IFN alfa 53 mineral density 53 deep venous thromboses 53 Severity Index PASI 53 detrusor overactivity 53 μg liter 53 myocardial infarction 53 concomitant medications 53 Exclusion criteria 53 amoxicillin clavulanate 53 #.#mg/dL 53 events MACE 53 ANOVA 53 arterial thromboembolic events 53 NMIBC 53 anemia hemoglobin 53 untreated mice 53 statistical significance p 53 tapentadol ER 53 Median survival 53 pericardial effusion 53 WOMAC TM 53 plasma HCV RNA 53 nmol 53 logistic regression analysis 53 fasting plasma glucose FPG 53 YMRS 53 serum potassium 53 multivariate adjusted 53 Scale EDSS 53 CK MB 53 SBM frequency 53 SBMs 53 apnea hypopnea index 53 spontaneous bowel movements 53 serum HBV DNA 53 extracapsular extension 53 mcg Albuferon 53 % CI #.#-#.# [004] 53 #.#ng/ml 53 Kaplan Meier survival 53 leuprorelin 53 fractional anisotropy 53 multivariable adjusted 53 HBeAg 53 symptomatic intracerebral hemorrhage 53 disease progression 53 μg 53 = -#.# 53 eplerenone 53 NPH insulin 53 aspartate aminotransferase 53 ADCS ADL 53 detrusor 53 -#.# log# copies mL 53 mL/min/#.# m2 53 abdominal pain abdominal discomfort 53 aspartate aminotransferase AST 53 insulin detemir 53 prognostic factors 53 locoregional recurrence 53 response CCyR 53 Health Assessment Questionnaire 53 symptomatic VTE 53 plus gemcitabine 53 etanercept 53 subscore 53 adefovir 53 lactate dehydrogenase 53 lumen diameter 53 #mg/day [002] 53 ACR# response 53 distant metastases 53 neutropaenia 53 mRNA expression 53 virological response 53 radical prostatectomy RP 53 perioperative complications 53 LV dysfunction 53 Global Impression 53 CsA 53 glycated hemoglobin levels 53 CI #.#-#.# p = 53 left ventricular dysfunction 53 nonfasting triglyceride levels 53 IQR 53 mediastinal 53 plasma uric acid 53 titrated glipizide 53 sensory neuropathy 53 F FDG PET 53 fasting plasma glucose 53 ug kg 53 reoperation 53 postprocedure 53 Neuropsychiatric Inventory NPI 53 CIMZIA TM certolizumab pegol 53 HBV DNA 53 fraction LVEF 53 mg/m2 dose 53 APTIVUS r 53 rCBF 53 abacavir lamivudine 53 serum ALT 53 comorbidity 53 primary patency 53 akinesia 53 systolic diastolic 53 dysuria 53 mg p = 53 secondary efficacy endpoint 53 VcMP 53 p = ns 53 nodal metastases 53 % CI #.#-#.# [005] 53 genotypic resistance 53 thromboembolic events 53 mL min 53 partial remissions 53 ischemia driven 53 erythema 53 CIMZIA TM 53 nondiabetic 53 dyspareunia 53 glomerular filtration 53 hemodynamically significant 53 plus ribavirin 53 Pain Intensity 53 total knee arthroplasty 53 hypokalemia 53 cerebrovascular accident 53 endoscopic remission 53 echocardiographic parameters 53 CR CRu 53 lymphocyte count 53 spine BMD 53 secondary efficacy endpoints 53 XIENCE V demonstrated 53 HBeAg positive patients 53 urinary N telopeptide 53 rhGH 53 esomeprazole 53 urate lowering therapy 53 fatigue asthenia 53 mg tid 52 pruritus 52 elevated ALT 52 elevated IOP 52 mild renal impairment 52 baseline A1C 52 sinus rhythm 52 dalteparin 52 NSTEMI 52 ribavirin RBV 52 nonmetastatic 52 neurocognitive function 52 evaluable patients 52 OGTT 52 Rating Scale BPRS 52 prospectively stratified 52 femoral shaft fracture 52 MBq 52 nadolol 52 achieved CCyR 52 mg 52 hemoglobin Hb 52 depressive symptoms 52 budesonide pMDI 52 vasomotor 52 dexamethasone 52 CFQ R 52 Hb A1C 52 serum creatinine levels 52 nondepressed 52 linezolid 52 mU L 52 target lesion revascularization 52 #μg [002] 52 Kaplan Meier curves 52 coronary revascularization 52 baseline CD4 52 Insulin sensitivity 52 β blockers 52 #.#-#.# p = 52 unfractionated heparin 52 conduction velocity 52 stage IIIb IV 52 #.#mmHg 52 salmeterol fluticasone propionate 52 asthenia 52 nausea photophobia 52 Partial Response 52 IELT 52 myocardial infarction stroke 52 serum phosphate levels 52 lymphadenectomy 52 urinary albumin 52 8mg/kg 52 tHcy 52 lymphocytosis 52 hemoglobin A1c levels 52 mcg mL 52 creatinine 52 BCVA 52 ventricular function 52 oxygen desaturation 52 clinically meaningful improvements 52 mm Hg systolic 52 nM 52 intact parathyroid hormone 52 creatinine levels 52 μg ml 52 Hb 52 androgen suppression 52 AUCs 52 mcg linaclotide 52 salivary cortisol 52 serum magnesium 52 uM 52 mmHg p = 52 TRAS 52 pulmonary vascular 52 GnRH agonist 52 isoproterenol 52 fasting plasma 52 TDF FTC 52 viral load 52 FluCAM arm 52 UPDRS motor 52 HbA1C 52 doxorubicin cyclophosphamide 52 detectable HCV RNA 52 sUA 52 prespecified secondary 52 aminotransferases 52 dyspnoea 52 #mmHg [001] 52 flow mediated dilation 52 5FU 52 Y BOCS 52 nicardipine 52 HAM D# scores 52 LVSD 52 HAM D# 52 Oswestry Disability Index 52 QD dosing 52 segment binary restenosis 52 LEXIVA r 52 ATACAND 52 HIV uninfected 52 Elitek 52 overt nephropathy 52 fasting triglyceride levels 52 Fasting plasma glucose 52 serum urate 52 Multivariate analysis 52 hepatic insulin sensitivity 52 splenectomized 52 plus prednisone 52 Alzheimer Disease Assessment 52 severe hypoglycemia 52 adalimumab 52 Thrombolysis 52 demonstrated clinically meaningful 52 rs# [003] 52 rimonabant #mg 52 ventricular mass 52 pamidronate 52 Apidra ® 52 ezetimibe simvastatin 52 primary efficacy endpoints 52 Stent thrombosis 52 irbesartan 52 Timed Walk 52 mesalamine granules 52 plasma leptin 52 adefovir treated 52 non inferiority 52 pruritis 52 death reinfarction 52 -#.# mm Hg 52 sirolimus eluting stent 52 mg Androxal 52 #mg BID [002] 52 bivariate 52 logMAR 52 aOR 52 gadolinium enhancing 52 VT VF 52 creatine kinase MB 52 FOLFOX4 alone 52 ACTEMRA TM 52 glimepiride 52 headache nasopharyngitis 52 primary endpoints 52 EDSS 52 serum PTH 52 enthesitis 52 neurodevelopmental impairment 52 AUA Symptom Score 52 Operative mortality 52 FDA defined valvulopathy 51 ritonavir boosted 51 thromboembolic 51 urine albumin 51 radiographically 51 ketorolac 51 beta blocker therapy 51 left ventricular ejection 51 ALSFRS R 51 quetiapine 51 APACHE II 51 intramuscularly 51 underwent resection 51 mEq L 51 DMARD 51 nodular partial response 51 oral allopurinol 51 min -1 51 thromboembolism 51 randomized 51 seropositive patients 51 SUVmax 51 nmol l 51 NT proBNP 51 locoregional 51 AST ALT 51 nasopharyngitis headache 51 ug ml 51 asthma exacerbation 51 LS BMD 51 fructosamine 51 TIMP 51 visual acuity 51 URTI 51 Complication rates 51 pulmonary exacerbation 51 interferon alfa 2a 51 Serum creatinine 51 revascularizations 51 pT2 51 antiretroviral naïve 51 HRCT 51 microalbuminuria 51 neurologic progression 51 progesterone receptor negative 51 histological subtype 51 attain statistical significance 51 glycosylated hemoglobin HbA1c 51 cTnI 51 rebleeding 51 #ug [001] 51 distensibility 51 aPTT 51 histologic subtype 51 adjunctive ABILIFY 51 serum creatinine 51 cells mcL 51 #q# deletion syndrome 51 squamous histology 51 TMC# r 51 PASI 51 parenchymal 51 bivalirudin monotherapy 51 colorectal adenomas 51 TPV r 51 Multivariate analysis revealed 51 plus OBT 51 Left Ventricular Ejection Fraction 51 Adverse events 51 glycosylated hemoglobin levels 51 IU ml 51 serum aminotransferase levels 51 platelet reactivity 51 treatment emergent adverse 51 transaminase elevations 51 receiving prophylactic anticoagulation 51 moderate renal impairment 51 plus GP IIb 51 hemorrhagic complications 51 mg kg belimumab 51 hyperintensity 51 mg qd 51 recurrent atrial fibrillation 51 Lumbar spine 51 HRQL 51 malunion 51 enoxaparin 51 infarct 51 stomatitis 51 ertapenem 51 log# reduction 51 #Gy 51 subtrochanteric 51 eptifibatide 51 adenoma recurrence 51 hippocampal volumes 51 ALT normalization 51 bosentan 51 serum triglycerides 51 CRp 51 specific antigen PSA 51 postoperative complications 51 PsA 51 pmol liter 51 hematologic adverse 51 oxycodone IR 51 noncarriers 51 cerebral oxygenation 51 homozygotes 51 mg kg Hematide 51 μg L 51 elevated troponin 51 median CD4 51 rFSH 51 HRQOL 51 mitoxantrone plus 51 transaminases 51 depressive symptom 51 CSBMs 51 kg/m2 51 pulmonary arterial 51 prior relapsers 51 nonfatal stroke 51 XELOX 51 treated nonoperatively 51 DAPT 51 hydronephrosis 51 #.#mmol L [002] 51 BARACLUDE r 51 airflow obstruction 51 ventricular dilatation 51 gout flares 51 CNS LS 51 malignancy HCM 51 BMI ≥ 51 radiographic progression 51 revascularization procedures 51 postinjury 51 systolic 51 serum prostate 51 noninferiority 51 somatostatin analog 51 mU liter 51 phonophobia 51 intraabdominal 51 Index CDAI score 51 recurrent DVT 51 gestational age 51 hepatic enzymes 51 prostate cancer CaP 51 fluorouracil 51 NIHSS score 51 fractional shortening 51 docetaxel pretreated 51 SVR# 51 COPD exacerbation 51 #mg/m# [001] 51 NRTI sparing 51 specific alkaline phosphatase 51 thrombocytopenia 51 receiving APTIVUS r 51 QTc 51 ULORIC 51 graft occlusion 51 ejection fraction EF 51 locomotor activity 51 solifenacin 51 dehydroepiandrosterone sulfate 51 Q2W 51 nasal symptom 51 gadolinium enhancing lesions 51 T2DM 51 Kaplan Meier method 51 tumor recurrence 51 hypocalcemia 51 serum leptin 51 neointimal 51 Score TOS 51 abdominal circumference 51 nonoperative treatment 51 undetectable viral load 51 fluticasone salmeterol 51 T2 lesions 51 kg -1 51 Erythropoietic therapies may 51 odds ratios ORs 51 arterial oxygen saturation 51 lacunar 51 rho = 51 invasive carcinomas 51 Scale cognitive subscale 51 Ishak fibrosis score 51 serum uric acid 51 hypogonadal 51 sirolimus stent 51 pulmonary capillary wedge 51 serum albumin 51 intraobserver 51 non menstrual pelvic 51 postoperative AF 51 histopathological 51 TIMP 1 51 sumatriptan naproxen sodium 51 placebo PBO 51 kappa = 51 tumor histology 51 plus octreotide LAR 51 mL sec 51 lamivudine refractory patients 51 undetectable HCV RNA 51 prednisone prednisolone plus 51 postmenopausal osteoporotic women 50 olanzapine 50 CABG 50 glycosylated hemoglobin 50 gastroduodenal 50 interquartile range IQR 50 flutamide 50 neoadjuvant chemotherapy 50 IIIa inhibitor 50 colorectal carcinoma 50 rs# [004] 50 KRAS mutant tumors 50 HER2 expression 50 axillary lymph node 50 ARCOXIA 50 PREZISTA r arm 50 lymph node involvement 50 renal function 50 esophageal carcinoma 50 Score IPSS 50 aromatase inhibitor therapy 50 AGILECT R 50 arteriolar 50 CD4 + cell 50 mucosal healing 50 thyroglobulin 50 affective psychosis 50 PANSS Positive